News | 03 November 2026
Zydus Wellness consolidated net sales up by 74.6% in Q2 FY27
Nutralite achieved robust, double-digit growth across its portfolio
Nutralite achieved robust, double-digit growth across its portfolio
First commercial line comes online in December 2026 as CDMO scales capacity for GLP-1s and next-generation complex peptides
Sun Pharma invested Rs 778.4 crore in research and development during the quarter, equivalent to 4.8% of sales
Under the agreement, the companies will divide global commercialisation responsibilities across key international markets
PAT jumps 25.7% to Rs 60.2 crore
The impressive 22% growth rate significantly outpaces the broader Indian Pharmaceutical Market averages
The approval was granted under the U.S. FDA’s President’s Emergency Plan for AIDS Relief (PEPFAR) program
The performance reflects the benefits of the company's strategic transition from an active pharmaceutical ingredients (API) manufacturer to a finished dosage formulations (FDF) player
The company's flagship brand, Naprosyn, also crossed the Rs 100-crore sales milestone, marking another significant achievement
The company confirmed that the USFDA observations do not involve data integrity or cross-contamination
EBITDA surges 72%; Revenue growth outlook raised to 19-20%
Operating EBITDA rose to Rs 147 crore in Q2 FY27 from Rs 91 crore in the preceding quarter
Domestic sales grew 15% during the nine-month period
.png){kind=logo}
Dual events to spotlight India’s manufacturing aspirations
Pharma major crosses Rs 14,000 million quarterly revenue milestone
The growth was driven by a resilient diabetes portfolio, robust export performance and tighter cost management
The strong quarterly performance was backed by improved gross margins, which increased to 63% from 59.9% in the year-ago quarte
Subscribe To Our Newsletter & Stay Updated
